At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 5, 2026 at 16:05 ET
Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clinical progress in its two allogeneic CAR-T programs, vispa-cel and CB-011, with upcoming data readouts expected in 2026. Revenue increased modestly, while R&D and G&A expenses declined due to workforce reductions and pipeline prioritization. The company reported a GAAP net loss of $148.1 million, including a $21.3 million non-cash impairment charge, and ended the year with $142.8 million in cash, sufficient to fund operations into 2H 2027.
- Licensing and collaboration revenue increased to $11.2 million in 2025 from $10.0 million in 2024.
- R&D expenses decreased to $109.4 million in 2025 from $130.2 million in 2024 due to cost-cutting measures.
- GAAP net loss was $148.1 million in 2025, slightly improved from $149.1 million in 2024.
- Non-GAAP net loss improved to $126.8 million in 2025 from $149.1 million in 2024, excluding $21.3 million in non-cash impairment charges.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access